Investor & technology day JULY 2021 AGENDA 9:30 - 10:50 AM ET | BUSINESS PRESENTATIONS ANGIODYNAMICS OVERVIEW GROWTH STRATEGY & TECHNOLOGY OVERVIEW KEY TECHNOLOGY PLATFORM OVERVIEW Thrombus management - ANGIOVAC & ALPHAV

1 Investor & technology day JULY 2021

AGENDA 9:30 - 10:50 AM ET | BUSINESS PRESENTATIONS ANGIODYNAMICS OVERVIEW GROWTH STRATEGY &

TECHNOLOGY OVERVIEW KEY TECHNOLOGY PLATFORM OVERVIEW Thrombus management - ANGIOVAC & ALPHAVAC PERIPHERAL ATHERECTOMY - AURYON IRREVERSIBLE ELECTROPORATION - NANOKNIFE VASCULAR ACCESS AND MED DEVICES GLOBAL HEALTHCARE ECONOMICS10:50 - 11:00

AM ET | FINANCIAL GOALS & CAPITAL ALLOCATION11:00 - 11:30 AM ET | Q&A

3 Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements

within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital

expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans,"

"projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks

and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without

limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or

assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other

regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party

distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the

effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of

AngioDynamics to obtain regulatory clearances or approval of its products, or integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on

Form 10-K for the year ended May 31, 2020. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.In the United States, the NanoKnife System has received a 510(k) clearance by the

Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of

a specific disease or condition.Notice Regarding Non-GAAP Financial MeasuresManagement uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in

AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics

has included adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing

AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review

AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on

AngioDynamics' financial results.

4 Disclaimers:This presentation includes videos of key opinion leaders, who are paid consultants of

AngioDynamics. The views and opinions expressed by these key opinion leaders are their own and do not necessarily reflect the views and opinions of AngioDynamics.The FDA-approved/cleared labeling for all products may not be consistent with all

uses described herein. These videos are in no way intended to promote the off-label use of medical devices. AngioDynamics only markets its products in accordance with their cleared or approved labeling.

AngioDynamics has a rich history that is deeply rooted in upstate New York's region known as

"Catheter Valley." The Company has grown through its many phases to become a global, industry-leading provider of high-quality medical technology used by physicians for the treatment of cancer and peripheral vascular disease. 33 YEARS

PURSUE LARGER, FASTER GROWING MARKETSActive portfolio management enables us to compete in larger,

faster growing markets relying on technology & innovation to produce measurable patient outcomes DEPLOY FOCUSED RESOURCE DEVELOPMENTResource deployment focused in areas that offer better opportunities for success DRIVE PORTFOLIO

TRANSFORMATIONPortfolio transformation & strength driven by R&D, M&A, and Clinical & Regulatory ATTRACT AND RETAIN TOP TALENT Strong and innovative portfolio combined with top talent drives value STRATEGIC TRANSFORMATION

Diagnostic Catheters, Guidewires and Kits Vascular Access Catheters and Accessories Microwave &

Radiofrequency Tumor Ablation Endovenous Laser Treatment Lung Biopsy Safety Radiation Treatment Stabilization Balloons MED TECHInvest for Growth MED DEVICEMaintain Positioning Thrombus Management Irreversible Electroporation Peripheral

Atherectomy AlphaVac commercial launch planned for 4th quarter calendar year 2021.

Focus on Innovative Medical Technologies Leveraging three main drivers to carve out our space in

large, growing markets through innovative, disruptive technologies that treat patients with cancer, promote healthy blood flow and deliver critical therapies. M & A R & D Clinical & Regulatory Pathway Expansion Advancing Our

FOCUSED TRANSFORMATIONU.S. Total Addressable Markets FY2021 Launch of the Auryon System gives us

access to the peripheral atherectomy market Planned Thrombectomy & NanoKnife System portfolio additions & new indications increase market access $3.0B 2-5% Mkt CAGR $5.5B 3-7%Mkt CAGR $8.0B 3-7%Mkt

CAGR FY2023 FY2025 The planned portfolio additions and new indications are not guarantees of future performance and are subject to risks and uncertainties including FDA clearance. Investors are cautioned that actual events or results may

differ from AngioDynamics' expectations. Planned Thrombectomy & PE portfolio additions & new indications increase market access Began our strategic initiative to become a growth company FY2018 $1.3B 0-3% Mkt CAGR

TECHNOLOGY PIPELINE FY22 FY23 FY24 Thrombus Management Peripheral Atherectomy AlphaVac F2220,

F22180 AlphaVac F1885 AngioVac F1885 AlphaVac F1885 PE, IDE Approval AlphaVac Lower Extremity (DVT), Smaller Cannula Auryon 2.0 Catheter Enhancements Prostate PRESERVE Study Irreversible Electroporation Pancreas

DIRECT Study Auryon Expanded Indication PAD Line Extensions PRODUCT LAUNCHES REGULATORY CLEARANCES REIMBURSEMENT SUPPORT The planned portfolio additions and new indications are not guarantees of future performance and are subject to

risks and uncertainties including FDA clearance. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. IDE Study

THROMBUS MANAGEMENT MED TECH

Deep Vein ThrombosisDVT + Pulmonary EmbolismPE = Venous ThromboembolismVTE A blood clot that forms

in a deep vein, usually the leg, groin or arm A DVT breaks free from a vein wall and travels to the lungs blocking some or all of the blood supply DVT and PE are collectively referred to as VTE 208,000 Iliofemoral Cases1 171,000 High-risk

& intermediate-risk PE Cases1 VTE Affects up to 900k Americans each year100,000 VTE-Related Deaths in the USA Annually2Roughly 30% of Americans who get a blood clot will have a reoccurrence in less than 10 yearsVTE Costs our US Healthcare

system $10 Billion a year Stages of Clot Clot in Transit (traveling through the heart) Clot in Pulmonary Arteries (PE) 1. Plovanic, W. J., & Furlong, C. (2020, June). Inari Medical Biomedical Devices and Services. Canaccord

Genuity Capital Markets.2. "Venous Thromboembolism (VTE)." World Thrombosis Day, www.worldthrombosisday.org/issue/vte. Illustrations and Images not Produced by AngioDynamics Include:https://www.vascularmedcure.com/disease-backgroundDVT (Blood

Clot In the Leg): 7 Warning Signs and Symptoms (emedicinehealth.com) VTE Represents 390k Cases Annually https://www.cdc.gov/ncbddd/dvt/data.html

13 DVT & PE TREATMENT OPTIONSPercutaneous Thrombectomy CDT & US-CDTCatheter-Directed

Thrombolysis (with or without the assistance of ultrasound) PCMTPharmacomechanical Thrombectomy Continuous Aspiration Suction Thrombectomy MTMechanical Retrieval Thrombectomy MAMechanical Aspiration(Small & Large) Lytic

Based Non-Lytic Based Rx AnticoagulationPrescription Medication SIMPLE COMPLEX MODERATE Treatment "Type" Spectrum Illustrations and Images not Produced by AngioDynamics Include:https://youtu.be/0QUUBZ6BxSo

https://www.penumbrainc.com/indigo-lightning/ https://www.vascularmedcure.com/ourproducts Active Portfolio Development

The Difference The AngioVac System allows for the continuous aspiration of embolic material such as

fresh, soft thrombi or vegetation from the venous systemUtilizing a self-expanding, nitinol reinforced funnel tipSimultaneously reinfusing the patient's own filtered blood to limit procedural blood loss Centrifugal Pump Console Waste

Collection System Filter Saline AngioVac Cannula Reinfusion Cannula AngioVac Circuit Individual experience may not be indicative of all procedure results.

THE NEXT GENERATION OF ANGIOVACPhysician requests for use in DVT drive new product

development $1.6B Controlled Powerful Versatile THE NEXT PORTFOLIO INNOVATION A purpose-built, innovative product leveraging the strengths of the AngioVac cannula technology with off-circuit manual aspiration control Proven funnel tip

design allows efficient aspiration and compression of large clot burden Designed to allow the end-user command and control of the mechanical aspiration Broadens Thrombus Management portfolio and is designed to provide an intuitive, first-line

treatment option without the need for lytics and advanced procedural support AlphaVac commercial launch planned for 4th quarter calendar year 2021.

Handle | Control Features DIRECTIONAL LABELSCannula | Waste Bag SYRINGE BARREL DURABLE LABELSVisible

in low light environments VOLUME LIMITING SWITCHIntuitive location | Multiple glove sizes VACUUM LOCKControlled, single-hand design ANGLED HILTEasy access to vacuum lock TEXTURED GRIPEnhances grip control ROBUST DESIGNEnables smooth

pulls with contemporary design ANGLED EXIT Prevents large thrombus clog MALE AND FEMALE CONNECTION Ensures correct connection SPACERAllows sterile blood path and confirms plunger passes shelf-life constraints

F1885 Cannula | Simple Design. Powerful Features. Tapered Distal TipEnhanced navigation and

safety Lubricious Shaft MaterialEasy delivery through tortuous anatomy Hemostasis ValvePrevents blood loss during device exchange Quarter Turn ValveLocks tip angle in place Side Arm Flush PortRemove air between sheath and

cannula Radiopaque Tapered Soft TipEnhanced visibility Atraumatic transition to obturator Funnel Shaped HandleGuided device insertion Quick Connect Handle Alignment RibIndicates cannula curve Triple Durometer Braided ShaftStiffness for

powerful push, terminates with a more flexible atraumatic distal end with 1:1 torque Nitinol Reinforced Funnel TipReliable clot entrapment and removal 85 Cannula BendEnhanced direct-ability OBTURATOR SHEATH CANNULA AlphaVac F1885 is

not cleared by the Food and Drug Administration (FDA). These statements and the subject product have not been evaluated by the FDA. The device is not currently being marketed, nor is it available for sale in any country.

Purpose-Built Portfolio to Address the Removal of Clot & Thrombus from Neck to Knee

F22180 Represents the French Size of our cannula Represents the Angle/Degree of our cannula tip Example AngioVac & AlphaVac Nomenclature F2220 F22180 F1885 F1310 F1885 PE NA AlphaVac commercial launch planned for 4th

quarter calendar year 2021. AlphaVac F1885 and F1310 are not cleared by the Food and Drug Administration (FDA). These statements and the subject product have not been evaluated by the FDA. The device is not currently being marketed, nor is it

available for sale in any country.

ADDRESSABLE MARKETThrombus Procedures by Location Right Heart/Atrium97K Patients$77M TAM IVC/SVC -

Caval DVT20K Patients$360M TAM PE167K Patients$1.6B TAM Popliteal - DVT95K Patients$300M TAM Ilio-Femoral - DVT246K Patients$700M TAM RESTORATIVE FLOW THERAPIES Funnel TipOpening FR Size Cannula AngleDegree Cannula FR

Size ModalityType F2220 F22180 F1885 F1310 F1885 PE 42FR 42FR 33FR ~16FR 33FR 20 180 85 10 85 22FR Cannula25FR Sheath 22FR Cannula25FR Sheath 18FR Cannula22FR Sheath 13FR Cannula16FR Sheath 18FR Cannula22FR

Sheath Deliberate Attention to Key Technology Elements Shapes, Sizes and Angles will be available in both on/off circuit options (AlphaVac/AngioVac) Availability FY22 Q2/3 FY22 Q2/3 FY22 Q3* FY23 Q4* FY24 Q4* AlphaVac F1885 and F1310

are not cleared by the Food and Drug Administration (FDA). These statements and the subject product have not been evaluated by the FDA. The device is not currently being marketed, nor is it available for sale in any country. AlphaVac and

AngioVac are not indicated for PE. AlphaVac commercial launch planned for 4th quarter calendar year 2021.

Objective: To evaluate the patterns of use, safety and effectiveness data of the AngioVac device in bulk

removal of endovascular material. Principal Investigator: Dr. John Moriarty, UCLANumber of patients enrolled: 234Number of sites: 21Recruitment goal: 200Timeline: 2016 - 2019 REGISTRY OF ANGIOVAC PROCEDURES IN

Right Heart Mass: 123Caval thromboembolism*: 91Catheter related thrombus: 25Pulmonary embolism*:

7Combination of above = 5.6 % 5.6% 1.7% 8.5% 35.9% 48.3% Right Heart Mass Caval thromboembolism Catheter related thrombus Pulmonary embolism Combination * The AngioVac Cannula is indicated for use as a venous drainage

cannula and for removal of fresh, soft thrombi or emboli. Use of the AngioVac cannula in the Pulmonary Arteries is off-label. All procedures performed in the registry using the Generation 2 cannula. Moriarty et al, Endovascular removal of

thrombus and right heart masses using the AngioVac system. Results of 234 patients from the prospective multicenter registry of AngioVac procedures in detail (RAPID). JVIR. Accepted * Rounding decimals to the nearest whole number RAPID -

First large scale prospective multicenter assessment of the AngioVac system. RAPID -

KEY TAKEAWAYS Effective: Majority of patients have > 70% clot/mass removed. Safe: 75% of all cases no RBC transfusion with 6 (2%) major hemorrhage, 1 procedure-related death.

Seek FDA clearance for Pulmonary Embolism Indication: Determine the safety and effectiveness of the

AlphaVac F1885 in a prospective trial of patients with acute intermediate-risk pulmonary embolism (PE)Patient Enrollment Target: 122Timeline: 2022-2024, Currently in study design discussions with FDA PE IDE Study: A Prospective, Multicenter,

MANAGEMENTPurpose Built Portfolio & Technology 26 Right Atrium AngioVac's use is currently focused on the Right Atrium, which is a $77M addressable market. Pulmonary Embolism Deep Vein Thrombosis AlphaVac, a multi-purpose mechanical

aspiration device, will allow us to compete in the broader DVT & PE addressable markets ($2.9B) with a first-line treatment option without the need for perfusion. C U R R E N T P O R T F O L I O EXPANDED P O R T F O L I O DVT &

PE Uni-Fuse+ catheter directed thrombolysis now has the additional indication for placement in the pulmonary artery. C U R R E N T P O R T F O L I O SIMPLE COMPLEX MODERATE $3B $77M2 $1.3B1 $1.6B1 PULMONARY EMBOLISM RIGHT

ATRIUM DEEP VEIN THROMBOSIS Plovanic, W. J., & Furlong, C. (2020, June). Inari Medical Biomedical Devices and Services. Canaccord Genuity Capital Markets. Fletcher Spaght, Inc. AngioVac market assessment March 2018, AngioDynamics

funded AlphaVac commercial launch planned for 4th quarter calendar year 2021.

THROMBUS MANAGEMENTPlanned Portfolio Additions & U.S. Addressable Markets

Expansion $1.3B FY 2021 FY 2022 FY 2023 FY 2025 FY 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 $140M $700M $3.6B $1.5B 1 2 The planned portfolio additions are not guarantees of future

performance and are subject to risks and uncertainties, including clearance by the FDA. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. (F2220, F22180)Right Atrium, Illio-caval DVT (F2220 -

F22180 - F1885Entry into Ilio-femoral DVT (F1310)Access to full Ilio-femoral DVT market (F1885) Smaller size should drive further adoption in addressable market PE Indication (F1885 PE) Purpose Built, Comprehensive, Thrombus

Portfolio F2220 F22180 F1885 1885 PE F1310 Continuous Aspiration with Simultaneous Reinfusion Multi-purpose Mechanical/Manual Aspiration Catheter Directed Thrombolysis with PE Indication F2220 F22180 F1885 1885 PE F1310